Often called the "master antioxidant," glutathione is a tripeptidea small protein made of three amino acids: cysteine, glutamine, and glycine
RhuGM CSF in combination with standard induction chemotherapy ("3+7") in patients with de novo acute myeloid leukemia
How it works: GHRH receptor agonism (CJC-1295): binds pituitary somatotrophs via the GHRH receptor, amplifying baseline GH pulse amplitude and duration over the course of days due to albumin binding Ghrelin receptor agonism (Ipamorelin): activates GHS-R1a with an earlier onset and more immediate GH secretion spike compared to GHRH analogs, providing a complementary time profile Sequential synergy: the two peptides act on distinct receptor systems and exhibit a combined GH output greater than either alone, with ipamorelin providing the acute peak and CJC-1295 sustaining elevated trough levels IGF-1 elevation: downstream GH signaling raises circulating IGF-1, the primary mediator of tissue repair, protein synthesis, and connective tissue remodeling
Our factory covers an area of more than 15, 000 square meters and has 8 production lines
Reported biological activities in research include: Modulation of angiogenesis-related signaling pathways in experimental models Investigation of gastrointestinal protective mechanisms Influence on nitric oxide-related cellular signaling Study of oxidative stress and inflammatory response pathways Examination of connective tissue and extracellular matrix-related processes Investigation of neuronal response and neuroprotective mechanisms in laboratory models Current evidence remains limited, and further well-controlled clinical studies are required to establish long-term efficacy and safety in humans